Related Experiment Video
Updated: Jan 12, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Limited Predictive Performance of the SAMe-TT₂R₂ Score for Suboptimal Time in Therapeutic Range (TTR) in Thai
Panisa Manasirisuk1, Thunchanok Kuichanuan2, Witsarut Manasirisuk2
1Department of Pharmacy, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, THA.
Background:
The SAMe-TT₂R₂ score is used to predict poor anticoagulation control (time in therapeutic range (TTR)) in warfarin users. However, its performance varies across ethnicities, and its validity in the Thai population is uncertain. This study aimed to evaluate the score's predictive performance and redefine the optimal cutoff for Thai patients with atrial fibrillation (AF).
Methodology:
This retrospective analysis included 140 patients with non-valvular AF on warfarin at a single University Hospital. TTR was calculated using the Rosendaal method, with suboptimal control defined as TTR <70%. The score's overall predictive performance was assessed using the area under the ROC curve (AUC).
Results:
The mean of TTR was 59.89% ± 28.56%, and 83 patients (59.3%) had suboptimal TTR. The SAMe-TT₂R₂ score ≥3 demonstrated poor predictive ability for suboptimal TTR (AUC = 0.55; 95% confidence interval (CI), 0.50-0.60). At this cutoff, key diagnostic metrics included high sensitivity (95.2%) but extremely low specificity (14.0%), a modest positive predictive value (PPV) of 61.7% and a low negative predictive value (NPV) of 66.7%. Notably, in multivariable analysis, age <60 years, a risk factor in the original score, was independently associated with a lower risk of suboptimal TTR. A longer duration of warfarin use was also associated with a lower risk of suboptimal TTR.
Conclusions:
The SAMe-TT₂R₂ score showed poor performance in predicting suboptimal TTR in our Thai cohort and has limited clinical utility. The score cannot reliably rule in or rule out patients at risk for poor control. Clinical decisions, such as intensive monitoring or switching to a direct oral anticoagulant (DOAC), should be guided by a patient's actual TTR rather than the SAMe-TT₂R₂ score. The single-center, retrospective design and modest sample size limit generalizability and statistical power, necessitating a further prospective trial for validation.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Therapeutic Drug Monitoring: Drug Analysis Methods

